In this segment, Dr. Peter Voorhees presents a modified case involving a patient in their early 70s with relapsed multiple ...

In this segment, Dr. Peter Voorhees and Dr. Doris Hansen discuss the safety profile and post-treatment management of CAR ...

In this segment, Dr. Luciano Costa provides practical considerations for managing patients with newly diagnosed multiple ...

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses the biological rationale for targeting ...

In this segment, Dr. Peter Voorhees and Dr. Luciano Costa discuss how treatment selection can be individualized for patients with newly diagnosed multiple myeloma, including considerations when ...

In this segment, Dr. Peter Voorhees and Dr. Luciano Costa discuss the design and clinical implications of the CEPHEUS trial in newly diagnosed multiple myeloma, with particular attention to patients ...

Daniel DeAngelo, MD, PhD, discusses how the field of AML is moving away from traditional chemotherapy and toward targeted ...

The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free ...

Investigators stated that the results support the proposed mechanism that both retained HER2 expression and elevated CD47 levels may drive efficacy through enhanced antibody-dependent cellular ...

Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to ...

Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to ...

Durability metrics included median duration of response 29.1 months and median PFS 30.2 months, with ongoing responses ...